2024/12/30 by Amdouni R ., Ajmi H ., Ben Ahmed S . +3
#Hémangiomes infantiles #Infantile hemangiomas #beta-blockers #bétabloquants #corticosteroids #corticoïdes #embolisation #embolization #intralesional therapy #laser #thérapie intra-lésionnelle
paper · doi:10.71566/pist-rmp-194615
Infantile hemangiomas (IH) are one of the most common vascular tumors in children. They are benign vas- cular endothelial neoplasms that follow a predictable clinical course usually appearing during the first three weeks of life, then entering a proliferative phase, characterized by rapid growth between three and nine months, followed by slow spontaneous regression and tumor involution. They are heterogeneous tumors that vary in size, depth, location and growth pattern. A multimodal and multidisciplinary approach is the- refore often necessary. Most IH resolves spontaneously, but a subset of affected patients are at risk for complications in 10 to 20% of cases. The prognosis of IH can be linked to aesthetic, functional but also and above all vital damage (due to the location of the IH). Therapeutic management varies from therapeutic abstention to surgical treatment. Uncomplicated focal IH progresses spontaneously beyond twelve mon- ths. Complicated IH or complex forms (PHACES syndrome, diffuse neonatal hemangiomatosis, etc. ) require medical treatment. Propranolol, a non-cardio-selective beta-blocker, represents the mainstay of systemic treatment of hemangiomas in patients older than five weeks. In this article, we carried out a review of several scientific articles in order to take stock of the different therapeutic approaches and propose a deci- sion-making algorithm for the management of IH.